Table 2

Crude and adjusted rateratios of pneumonia associatedwith current use ofpramipexole relative to otherdopamine agonists
Cases Controls Crude Adjusted*
Rate Ratio Rate ratio 95% CI
Number of subjects 1835 16,088
Current use† of (%)
 Pramipexole (%) 59 (3.2) 734 (4.6) 0.80 0.85 0.62 – 1.17
 All other dopamine agonists (%) 210 (11.4) 2112 (13.1) 1.00 1.00 Reference
 Pramipexole (%) 59 (3.2) 734 (4.6) 0.90 0.95 0.68 – 1.35
 Non-Ergot-derived dopamine agonists (%) 101 (5.5) 1157 (7.2) 1.00 1.00 Reference
 Pramipexole (%) 59 (3.2) 734 (4.6) 0.72 0.75 0.53 – 1.08
 Ergot-derived dopamine agonists (%) 109 (5.9) 966 (6.0) 1.00 1.00 Reference

* Adjusted for current use of other anti-parkinsonian drugs, including levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all factors listed in Table 1.

† Current use refers to a prescription ending after or within 30 days prior to the index date.

Ernst et al.

Ernst et al. BMC Neurology 2012 12:113   doi:10.1186/1471-2377-12-113

Open Data